Evaporative dry eye disease (DED) is a common ocular condition impacting the quality of life of millions of patients worldwide. The etiology of evaporative DED is related to dysfunction of meibomian glands (MGs), resulting in suboptimal yield or lipid composition of secreted meibum. The clinical manifestation of evaporative DED involves mechanical obstruction of the MG orifice and decreased tear film stability that leads to chronic eye irritation, inflammation, and progressive damage to the cornea and surrounding tissue. Despite its high prevalence, evaporative DED remains an unmet medical need. The main obstacle in the development of effective therapeutic strategies against this disease is inadequate knowledge about the complex arrays of lipogenic reactions (meibogenesis) in the MGs and a lack of suitable animal models of the human condition. In this review, we discuss the recent advances in the creation of genetically modified mouse models that recapitulate the phenotype of evaporative DED as well as their impact on our understanding of lipid biosynthesis in MGs and therapeutic strategies targeting meibogenesis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185702 | PMC |
http://dx.doi.org/10.1016/j.exer.2022.109072 | DOI Listing |
J Clin Med
January 2025
GI-2092-Optometry, Departamento de Física Aplicada (Área de Optometría), Universidade de Santiago de Compostela, Campus Vida s/n, 15701 Santiago de Compostela, Spain.
: The aim of the present study was to establish a cut-off value of the Lipid Layer Pattern (LLP) between participants with different subtypes of Dry Eye Disease (DED) including Deficient Dry Eye (ADDE), Evaporative Dry Eye (EDE), and Mixed Dry Eye (MDE). : 240 participants diagnosed with DED according to the Tear Film and Ocular Surface Society in the Dry Eye Workshop II guidelines were included in the study. Tear Meniscus Height (TMH) using the Tearscope illumination and Meibomian Gland Loss Area (MGLA) using the Keratograph 5M were assessed to categorize the participants into an ADDE group, EDE group, or MDE group.
View Article and Find Full Text PDFClin Ophthalmol
January 2025
Department of Ophthalmology, Cardinal Tien Hospital, New Taipei City, Taiwan.
Background: Meibomian gland dysfunction (MGD) is a primary cause of evaporative dry eye disease (DED), which is often exacerbated by cataract surgery due to surgical trauma and inflammation. Thermal pulsation therapy (TPT) aims to enhance meibomian gland function and relieve dry eye symptoms. We conducted a systematic review and meta-analysis to evaluate the effectiveness of TPT in managing dry eye symptoms associated with cataract surgery.
View Article and Find Full Text PDFOphthalmol Ther
February 2025
Santa Barbara Eye Care, Santa Barbara, CA, USA.
Perfluorohexyloctane ophthalmic solution (Miebo) and water-free cyclosporine ophthalmic solution 0.1% (Vevye) are recently approved treatments for dry eye disease (DED). Perfluorohexyloctane (PFHO) uses a novel approach to treat evaporative DED, whereas water-free cyclosporine (CsA 0.
View Article and Find Full Text PDFCornea
November 2024
Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY.
Purpose: To visualize the behavior of perfluorohexyloctane (PFHO), an eye drop to treat dry eye disease (DED), on the surface of saline in vitro and on the human ocular surface using infrared emissivity.
Methods: Emissivity videos were used to measure the spreading and disappearance rates of PFHO on saline (with and without mucin for spreading rate) and layered over a 125 nm film of meibum on the surface of saline using a TearView camera. Ocular surface emissivity was videoed in a volunteer without DED before and after instillation of 1 drop of PFHO.
Expert Opin Pharmacother
January 2025
Eye Clinic, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.
Introduction: Meibomian Gland Dysfunction (MGD) represents the most common cause of dry eye disease (DED). Traditional treatments mainly rely on heating and liquifying the meibum to favor its expression. However, recent knowledge advances have led to the development of novel therapies specifically designed for patients with MGD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!